Navigation Links
Oramed Pharmaceuticals Announces Reverse Stock Split
Date:1/22/2013

JERUSALEM, January 22, 2013 /PRNewswire/ --

Oramed Pharmaceuticals Inc. (OTCQB:ORMP) (http://www.oramed.com), a developer of oral drug delivery systems, announced today that its previously announced one for twelve reverse stock split has become effective. As of the open of business on January 23, 2013, the shares of Oramed will be trading on a reverse split-adjusted basis on the OTCQB Market under the symbol "ORMPD," which replaces the previous symbol "ORMP" for the next 20 business days. Oramed effected the reverse stock split in order to help it meet the qualifications for listing its shares on the Nasdaq Capital Market.  

The reverse split reduces the number of shares of Oramed's authorized shares of common stock from approximately 200,000,000 to approximately 16,666,667 and outstanding shares common stock from approximately 86,505,020 to approximately 7,209,652. The exercise price and the number of shares of common stock issuable under Oramed's outstanding warrants and options have been proportionately adjusted to reflect the reverse stock split. Fractional shares created as a result of the stock split will be rounded up to the next whole share.

 "We are taking steps to move our company forward on many fronts and this reverse stock split puts us closer to our goal of up-listing to a major market in the U.S.," commented Oramed CEO, Nadav Kidron .

About Oramed Pharmaceuticals

Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs and vaccines currently delivered via injection. Established in 2006, Oramed's technology is based on over 30 years of research by top research scientists at Jerusalem's Hadassah Medical Center. Oramed is seeking to revolutionize the treatment of diabetes through its proprietary flagship product, an orally ingestible insulin caps
'/>"/>

SOURCE Oramed Pharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Oramed Pharmaceuticals Granted 2nd Patent in New Zealand; 3rd Patent for Core Technology on Oral Delivery of Proteins
2. Todays Research on Mylan and Watson Pharmaceuticals: One Drug Makers Sorrow is Another Ones Joy
3. Biscayne Pharmaceuticals Closes $1.5 Million Financing To Advance Recent Discoveries Of Pioneering Endocrine Drug Researcher
4. UPM Pharmaceuticals Enhances its Pre-Formulation Capabilities
5. Biosim Pharmaceuticals, Manufacturers of Generic ACTHAR, to Participate at Biotech Showcase 2013
6. Rafarma Pharmaceuticals, Inc. Achieves Full Certification
7. Auxilium Pharmaceuticals, Inc. to Present At The Oppenheimer 23rd Annual Growth Conference
8. Inovio Pharmaceuticals Announces Positive Interim Results in Phase II Leukemia Trial
9. Gallus BioPharmaceuticals Announces Appointment of Senior Baxter Executive as Chief Commercial Officer
10. Ampio Pharmaceuticals, Inc. (AMPE) announces appointment of Josh Disbrow as Chief Operating Officer effective December 15, 2012
11. Inovio Pharmaceuticals Cytomegalovirus (CMV) Synthetic Vaccine Constructs Generate Strong and Broad T-Cell Responses in Preclinical Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... Research and Markets( http://www.researchandmarkets.com/research/3nl6s2/neuroprotection ) has ... "Neuroprotection - Drugs, Markets and Companies" ... the role of neuroprotection in acute disorders such ... as well as in chronic diseases such as ... of damage to neural tissues are similar in ...
(Date:5/28/2015)... , May 28, 2015 Natera, Inc., ... a study published in Ultrasound in Obstetrics ... polymorphism (SNP)-based non-invasive prenatal test (NIPT) can identify ... A study based upon data ... pregnancies occur in about 1 in 1,000 pregnancies, ...
(Date:5/28/2015)... N.J. , May 28, 2015  PDS ... a cancer immunotherapy treatment targeting HPV-16, has generated ... Currently, pre-cervical cancer is treated by ... a simple and effective non-surgical alternative. Results show ... mechanisms (T-cells) to recognize, target, and kill precancerous ...
(Date:5/28/2015)... May 28, 2015  GenVec, Inc. (Nasdaq: GNVC ... Douglas J. Swirsky , will present a company overview ... a.m. EDT on Thursday, June 4, 2015. ... presentation will be available at the following link:  ... GenVec,s website.  To access, visit www.genvec.com , click ...
Breaking Biology Technology:Global Neuroprotection Market Report 2015-2024 - Drugs, Markets and Companies 2Global Neuroprotection Market Report 2015-2024 - Drugs, Markets and Companies 3First Confirmed Detection of a Complete Molar Pregnancy with Cell-Free DNA Test 2First Confirmed Detection of a Complete Molar Pregnancy with Cell-Free DNA Test 3PDS Biotechnology reports positive Phase I clinical trial results in proprietary HPV-Cancer Immunotherapy 2GenVec To Present At The Jefferies Healthcare Conference 2
... , CARLISLE, Mass., Aug. 5 ... launch of a fully integrated microarray solution platform. ... biochips and advanced microarray instrument systems, in collaboration ... and instrumentation software, now offers a platform that ...
... , CHICAGO, Aug. 5 Advanced ... it will host a conference call and webcast discussing the Company,s ... a.m. (EDT). Michael T. Flavin, Ph.D., Chairman & Chief Executive Officer, ... present an update on the Company. A press release reporting the ...
... Framework Reaffirmed , Shire plc (LSE: SHP, NASDAQ: SHPGY ) the global specialty,biopharmaceutical company, announces results for the ... ... Q2 2009(1), Product sales ... -21%, Product sales (excluding ADDERALL XR) $491 million ...
Cached Biology Technology:CapitalBio Corporation and VigeneTech Inc. Have Announced the Launch of a Fully Integrated Microarray Solution Platform 2CapitalBio Corporation and VigeneTech Inc. Have Announced the Launch of a Fully Integrated Microarray Solution Platform 3Advanced Life Sciences to Host 2009 Second Quarter Financial Results Conference Call and Webcast 2Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 2Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 3Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 4Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 5Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 6Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 7Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 8Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 9Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 10Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 11Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 12Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 13Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 14Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 15Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 16Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 17Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 18Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 19Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 20Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 21Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 22Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 23Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 24Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 25Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 26Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 27Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 28Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 29Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 30Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 31Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 32Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 33
(Date:5/14/2015)... 2015  Verificient Technologies, Inc., a technology ... remote proctoring, announced a new alliance partnership ... creator of the Canvas Learning Management System ... will benefit from the seamless integration of ... a fully integrated multifactor biometrics behavioral application, ...
(Date:5/8/2015)... JOSE, Calif. , May 8, 2015 Synaptics ... interface solutions, today announced that members of the executive management ... J.P. Morgan 43rd Annual Technology, Media and Telecom Conference ... Waterfront Hotel in Boston, MA ... May 27, 2015 Time: 2:45pm ET Location: The New York ...
(Date:4/27/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... growing mobile commerce market, announces that its Wocket® Smart ... week of May, 2015 and will be fulfilling all ... Gino Pereira , Chief Executive Officer said, ... Wocket® enters the consumer market. We would like to ...
Breaking Biology News(10 mins):Verificient and Instructure Announce Alliance Partnership to Provide Online Proctoring for K-12 and Higher Education Institutions 2Synaptics to Present at Upcoming Investor Conferences 2Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 2Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 3
... Ky. The University of Louisville today announced that ... into a license and research collaboration agreement with Novartis ... the potential to help transplant patients avoid taking anti-rejection ... for treatment of other diseases. The University ...
... Boston University School of Medicine (BUSM) suggests that epigenetics may ... relapse of cancer. The findings are published online in Volume ... The term epigenetics refers to the external modifications ... do not change the DNA sequence, but instead, they affect ...
... MA New insights into how human cytomegalovirus ... with infection spreads from pregnant mother to fetus ... translational researchers an exciting new avenue for investigation ... interventions. Using next generation sequencing and population genetic ...
Cached Biology News:University of Louisville researchers sign global licensing agreement 2University of Louisville researchers sign global licensing agreement 3BUSM researchers study epigenetic mechanisms of tumor metastasis for improved cancer therapy 2Research points to potential window for treating CMV and preventing mother-to-child transmission 2Research points to potential window for treating CMV and preventing mother-to-child transmission 3
... Designed to meet the ... this animal component-free medium supports ... high cell densities, while maintaining ... recombinant protein production using the ...
... This CLS number is ... created to easily match ... showing no availability yet, ... old Sigma-Aldrich number (Z36,327-8) ...
Originally developed for the culture of Drosophila; suitable for culture of other dipteran cell lines. Powder, Insect cell culture tested...
... This CLS number is a ... easily match Cornings product number. ... please order under the old ... customer service for assistance. ...
Biology Products: